Table 1. Patents focusing on α-synuclein that have not been announced in the pipeline.
α-syn: α-synuclein; PD: Parkinson’s disease; AD: Alzheimer’s disease; MSA: Multiple System Atrophy; DLB: Dementia with Lewy Body; GBA: Glucocerebrosidase gene name; ß-syn: ß-synuclein; Aß: amyloid-beta; siRNA: small interfering RNA; miRNA: microRNA; RNAi : RNA interference.
| Patent publication # | Year of publication | Assignee | Main claims |
|---|---|---|---|
| WO2013127918 | 2013 | Pharnext (Issy Les Moulineaux, France) | Use of acamprosate, baclofen, cinalcet, mexiletine, sulfasoxazol, torasemide to delay PD |
| WO2013063516 | 2013 | Neotop Bioscience (Dublin, Ireland) | New antibody panel for PD and other Lewy Body diseases |
| WO2013020368 | 2013 | Hong Kong university (Hong Kong, China) |
Rhodiola rosea extract (e.g. rosavin) as an α-syn oligomerization inhibitor |
| WO2012170899 | 2012 | Prothera (Reno, USA) | Protease or peptidase (prolyl oligopeptidase) for PD patients with GBA mutations |
| WO2012068405 | 2012 | ISIS Pharmaceuticals (Carlsbad, USA) | New oligonucleotide library to decrase α-syn expression |
| WO2011107544 | 2011 | Dr. Rentschlzer Holding (Laupheim, Deutchland) | Antibody library targeting α-syn for PD and synucleinopathies |
| WO2011056222 | 2011 | University of Pittsburg (Pittsburg, USA) | Anti-protein aggregate compound |
| WO2010129791 | 2010 |
University Of Medicine & Dentistry of New Jersey
(Somerset, USA) |
Use of miRNA to decrase α-syn expression |
| WO2010103515 | 2010 | Tel Aviv University (Tel-Aviv, Israel) | Use of ß-syn derived peptides to decrease α-syn aggregation |
| WO2010094090 | 2010 |
Katholleke University Leuven
(Leuven, Belgium) & University of Graz (Gras, Austria) |
Sodium/hydrogen exchange type-1 transport system inhibitors against α-syn toxicity |
| WO2010060073 | 2010 | Tel Aviv University (Tel-Aviv, Israel) | Bacteriophage-based therapy for synucleinopathy |
| WO2010037135 | 2010 |
University Of California
(Oakland, USA) & Rosalind Franklin University of Medicine (Chicago, USA) |
Increasing clearance of protein aggregates by virus-mediated expression of chimeric polypeptide |
| WO2009086306 | 2009 | Whitehead Institute for Biomedical Research (Cambridge, USA) | List of target genes involved in α-syn toxicity |
| WO2009020624 | 2009 | University of Alabama (Tuscaloosa, USA) | SURF, SEC22 and Acyl CoA Oxidase alterations and modulations for PD |
| WO2008157425 | 2008 | University of California (Oakland, USA) | Use of polypeptide to slow protein aggregation in PD, AD, MSA, DLB |
| WO2008002465 | 2008 | Feinstein Institute For Medical Research (Manhasset, USA) | Guanylhydrazone compounds to prevent Aß and α-syn aggregation |
| WO2007135426 | 2007 | Isis Innovation (Oxford, GB) | Agents (RNAi, siRNA,DNA, ribozyme) to decrease α-syn expression levels |
| WO2006124892 | 2006 | Whitehead Institute for Biomedical Research (Cambridge, USA) | List of target genes involved in α-syn toxicity |
| WO2006091964 | 2006 | University of Alabama (Tuscaloosa, USA) | Methods for identification and targeting of genes involved in α-syn aggregation |
| WO2006073734 | 2006 |
Whitehead Institute for Biomedical Research
(Cambridge, USA) & University of Missouri (Missouri, USA) |
List of target genes involved in α-syn toxicity |
| WO2006039253 | 2006 | Children"s Memorial Hospital (Chicago, USA) | siRNA to decrease α-syn expression |
| WO0020020 | 2000 | University of California (La Jolla, USA) | Use of ß-syn as a dominant-negative effect to decrease α-syn aggregation |